Dublin, Jan. 22, 2016 -- Research and Markets (http://www.researchandmarkets.com/research/r9hfrx/nanobiotechnology) has announced the addition of Jain PharmaBiotech's new report "Nanobiotechnology Applications, Markets and Companies" to their offering.
An increasing use of nanobiotechnology by the pharmaceutical and biotechnology industries is anticipated. Nanotechnology will be applied at all stages of drug development - from formulations for optimal delivery to diagnostic applications in clinical trials. Many of the assays based on nanobiotechnology will enable high-throughput screening. Some of nanostructures such as fullerenes are themselves drug candidates as they allow precise grafting of active chemical groups in three-dimensional orientations. The most important pharmaceutical applications are in drug delivery. Apart from offering a solution to solubility problems, nanobiotechnology provides and intracellular delivery possibilities. Skin penetration is improved in transdermal drug delivery. A particularly effective application is as nonviral gene therapy vectors. Nanotechnology has the potential to provide controlled release devices with autonomous operation guided by the needs.
Nanomedicine is now within the realm of reality starting with nanodiagnostics and drug delivery facilitated by nanobiotechnology. Miniature devices such as nanorobots could carry out integrated diagnosis and therapy by refined and minimally invasive procedures, nanosurgery, as an alternative to crude surgery. Applications of nanobiotechnology are described according to various therapeutic systems. Nanotechnology will markedly improve the implants and tissue engineering approaches as well. Of the over 1,000 clinical trials of nanomedicines, approximately 100 are selected and tabulated in major therapeutic areas. Other applications such as for management of biological warfare injuries and poisoning are included. Contribution of nanobiotechnology to nutrition and public health such as supply of purified water are also included.
There is some concern about the safety of nanoparticles introduced in the human body and released into the environment. Research is underway to address these issues. As yet there are no FDA directives to regulate nanobiotechnology but as products are ready to enter market, these are expected to be in place.
Future nanobiotechnology markets are calculated on the basis of the background markets in the areas of application and the share of this market by new technologies and state of development at any given year in the future. This is based on a comprehensive and thorough review of the current status of nanobiotechnology, research work in progress and anticipated progress. There is definite indication of large growth of the market but it will be uneven and cannot be plotted as a steady growth curve. Marketing estimates are given according to areas of application, technologies and geographical distribution starting with 2015. The largest expansion is expected between the years 2020 and 2025.
Profiles of 248 companies, out of over 500 involved in this area, are included in the last chapter along with their 180 collaborations. The report is supplemented with 43 Tables, 27 figures and 820 references to the literature.
Key Topics Covered:
Executive Summary
1. Introduction
2. Nanotechnologies
3. Nanotechnologies for Basic Research Relevant to Medicine
4. Nanomolecular Diagnostics
5. Nanopharmaceuticals
6. Role of Nanotechnology in Biological Therapies
7. Nanodevices & Techniques for Clinical Applications
8. Nanooncology
9. Nanoneurology
10. Nanocardiology
11. Nanopulmonology
12. Nanoorthopedics
13. Nanoophthalmology
14. Nanomicrobiology
15. Miscellaneous Healthcare Applications of Nanobiotechnology
16. Nanobiotechnology and Personalized Medicine
17. Nanotoxicology
18. Ethical and Regulatory Aspects of Nanomedicine
19. Research and Future of Nanomedicine
20. Nanobiotechnology Markets
21. References
For more information visit http://www.researchandmarkets.com/research/r9hfrx/nanobiotechnology
Source: Jain PharmaBiotech
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Nanotechnology


Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Instagram Outage Disrupts Thousands of U.S. Users
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 



